Abstract: An apparatus comprises a main bench body; at least one slot located on the main bench body, the slot configured to slidably receive a bar in at least one fixed position; at least one bar comprising a shape configured to be slidably inserted into the slot on the main bench body in at least one fixed position; a back rest pivotally mounted to the main bench body; a seat rest pivotally mounted to the main bench body; and at least one support lever adjustably attached to the main bench body.

Abstract: A fastening tool having a nail stop which positions a nail for driving and is made at least in part of a contact material which can be investment cast and/or hardened. The contact material can resist wear from the action of driving the nail and the movement of a driver blade. The nail stop can be configured to align nails fed from a magazine and can be offset from the longitudinal centerline of the fastening tool. The nail stop can have a head contact length which is 0.5% to 95% of the length of the nail to be driven. The nail stop is used in methods for positioning a nail for driving.

Abstract: Described are methods for the assembly of monolayer, bilayer, or multi-layer structures composed of homogenous rod-like molecules and particles. Included are methods for tuning physical properties of the mono- or multi-layered structures by changing ionic conditions and the size or concentration of polymer used for self-assembly.

Abstract: Water-resistant waterborne acrylic coating materials, systems and methods providing enhanced water resistance and durability are provided. Such coatings extend the service life of roofing systems that are exposed to ponding water and other extreme weather conditions. Coatings described herein exhibit superior water resistance attributes including one or more of water infiltration resistance, wet tensile strength and wet adhesion.

Abstract: Described are methods for the assembly of monolayer, bilayer, or multi-layer structures composed of homogenous rod-like molecules and particles. Included are methods for tuning physical properties of the mono-or multi-layered structures by changing ionic conditions and the size or concentration of polymer used for self-assembly.

Abstract: A pharmaceutical composition containing a prostaglandin and an alkanoic acid ester of a polyethoxylated sorbitol in an amount effective to enhance the chemical stability of the prostaglandin, and the use thereof for treating ophthalmic conditions. Also disclosed are methods for enhancing the chemical stability of a prostaglandin-containing composition by using an alkanoic acid ester of a polyethoxylated sorbitol.

Abstract: A pharmaceutical composition containing a prostaglandin and an alkanoic acid ester of a polyethoxylated sorbitol in an amount effective to enhance the chemical stability of the prostaglandin, and the use thereof for treating ophthalmic conditions. Also disclosed are methods for enhancing the chemical stability of a prostaglandin-containing composition by using an alkanoic acid ester of a polyethoxylated sorbitol.

Abstract: The present invention relates to the use of tachykinin antagonists, including substance P antagonists and other neurokinin antagonists, in the treatment of emesis. Also described are novel tachykinin antagonists of formula (I), processes for their preparation, pharmaceutical compositions containing them and their medical use. wherein R represents the ring A ?or 2-pyridinyl or 2-pyridinyl-N-oxide; R1 is selected from halogen atoms and C1-4alkyl, C1-4alkoxy, trifluoromethyl, and S(O)nC1-4alkyl groups; R2 and R3, which may be the same or different, each independently are selected from hydrogen and halogen atoms and C1-4alkyl, C1-4alkoxy, trifluoromethyl and cyano groups; n represents zero, 1 or 2; and pharmaceutically acceptable salts and solvates thereof.

Abstract: The present invention relates to the use of tachykinin antagonists, including substance P antagonists and other neurokinin antagonists, in the treatment of emesis. Also described are novel tachykinin antagonists of formula (I), processes for their preparation, pharmaceutical compositions containing them and their medical use. wherein R represents the ring A or 2-pyridinyl or 2-pyridinyl-N-oxide; R1 is selected from halogen atoms and C1-4alkyl, C1-4alkoxy, trifluoromethyl, and S(O)nC1-4alkyl groups; R2 and R3, which may be the same or different, each independently are selected from hydrogen and halogen atoms and C1-4alkyl, C1-4alkoxy, trifluoromethyl and cyano groups; n represents zero, 1 or 2; and pharmaceutically acceptable salts and solvates thereof.

Abstract: A pharmaceutical composition containing a prostaglandin and an alkanoic acid ester of a polyethoxylated sorbitol in an amount effective to enhance the chemical stability of the prostaglandin, and the use thereof for treating ophthalmic conditions. Also disclosed are methods for enhancing the chemical stability of a prostaglandin-containing composition by using an alkanoic acid ester of a polyethoxylated sorbitol.

Abstract: The present invention relates to the use of tachykinin antagonists, including substance P antagonists and other neurokinin antagonists, in the treatment of emesis. Also described are novel tachykinin antagonists of formula (I), processes for their preparation, pharmaceutical compositions containing them and their medical use.

Abstract: The present invention relates to the use of certain tachykinin antagonists, including substance P antagonists and other neurokinin antagonists, in the treatment of emesis.

Abstract: The present invention relates to the use of NK1 antagonists, in the treatment of depression. Also described are novel NK1 antagonists of formula (I), processes for their preparation, pharmaceutical compositions containing them and their medical use. The compounds of formula I are as follows: having a formula (I) wherein R represents the ring A or 2-pyridinyl or 2-pyridinyl-N-oxide; R1 is selected from the group consisting of halogen atoms, C1-4alkyl, C1-4alkoxy, trifluoromethyl, and S(O)nC1-4alkyl groups; R2 and R3, which may be the same or different, each independently are selected from the group consisting of hydrogen atoms, halogen atoms, C1-4alkyl, C1-4alkoxy, trifluoromethyl and cyano groupss; n represents zero, 1 or 2; and pharmaceutically acceptable salts and solvates thereof.

Abstract: The present invention relates to the use of tachykinin antagonists, including substance P antagonists and other neurokinin antagonists, in the treatment of emesis. Also described are novel tachykinin antagonists of formula (I), processes for their preparation, pharmaceutical compositions containing them and their medical use. ##STR1## wherein R represents the ring A ##STR2## or 2-pyridinyl or 2-pyridinyl-N-oxide; R.sup.1 is selected from halogen atoms and C.sub.1-4 alkyl, C.sub.1-4 alkoxy, trifluoromethyl, and S(O).sub.n C.sub.1-4 alkyl groups;R.sup.2 and R.sup.3, which may be the same or different, each independently are selected from hydrogen and halogen atoms and C.sub.1-4 alkyl, C.sub.1-4 alkoxy, trifluoromethyl and cyano groups;n represents zero, 1 or 2;and pharmaceutically acceptable salts and solvates thereof.

Abstract: A multi-segmented utility belt which employs a plurality of substantially rigid sections connected by flexible portions. A variety of different tool holders can be pivotally and rotatably supported from the belt. The belt is provided with a hinge mechanism permitting an intermediate section to be inserted or removed from the left and right hand sections thus grossly varying the size of the belt.